** Shares of vaccine developer Vaxcyte PCVX.O down 51% at $34.04, lowest since October 2022
** Company says its experimental pneumococcal vaccine for infants, VAX-24, achieved "non-inferiority" in a mid-stage study compared to rival Pfizer's PFE.N Prevnar 20 shot
** Pneumococcal disease spreads through direct contact with respiratory secretions such as saliva or mucus and can cause fever, cough and chest pain
** Brokerage Guggenheim says the mid-stage data was consistent with co's expectations, but didn't meet high investor expectations, adding that the vaccine's immune response seems to be lower in children compared to adults
** Brokerage Jefferies says the stock pullback is mostly driven by the political headwind and anticipation of the data
** Jefferies also points to the "continued unfavorable market environment, particularly recent resignation of FDA CBER director who oversees vaccine"
** Shares of vaccine makers and other biotech companies have been falling as Wall Street Journal and other media outlets reported on Friday that Peter Marks, a top vaccine official at the U.S. FDA, has been pushed out of the agency
** Stock had fallen 62.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。